Results of Open Offer

29 March 2010

                             Scancell Holdings Plc                             

                                (the "Company")                                

                             Results of Open Offer                             

Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer
vaccines, is pleased to report the results of the Open Offer that was announced
on 5 March 2010.

Under the Open Offer, a total of 5,137,775 New Ordinary Shares will be issued
at a price of 45 pence per New Ordinary Share to raise approximately £2.31
million, before expenses, to fund the working capital requirements of the
Company.

Results of the Open Offer

  * Existing shareholders have subscribed for 3,770,248 New Ordinary Shares,
    representing approximately 73.38 per cent. of the total number of New
    Ordinary Shares to be issued;
   
  * Helium Special Situations Fund Limited, a new institutional investor, has
    subscribed for 1,034,194 New Ordinary Shares, representing approximately
    20.13 per cent. of the total number of New Ordinary Shares to be issued;
    and
   
  * 333,333 New Ordinary Shares have been placed with private investors,
    representing approximately 6.49 per cent. of the total number of New
    Ordinary Shares to be issued.
   
Admission and commencement of dealings in the New Ordinary Shares to be issued
under the Open Offer are expected to take place at 8.00 a.m. on 30 March 2010.
There will be a total of 15,413,326 ordinary shares in issue following
Admission of the New Ordinary Shares.

Directors' dealings

The Company has been notified of the following dealings:

Mr David Evans, non-executive chairman, has subscribed for 250,000 New Ordinary
Shares at 45p per share under the Open Offer. After Admission of the New
Ordinary Shares the total holding of David Evans in the Company will amount to
510,000 ordinary shares (representing approximately 3.31 per cent. of the
enlarged issued share capital).

Mr Michael Rippon, non-executive director, has subscribed for 55,000 New
Ordinary Shares at 45p per share under the Open Offer. After Admission of the
New Ordinary Shares the total holding of Michael Rippon in the Company will
amount to 250,416 ordinary shares (representing approximately 1.62 per cent. of
the enlarged issued share capital).

Mr Matthew Frohn, non-executive director, is also a director of Oxford
Technology Management Limited which is the manager for the Oxford Technology
VCT plc and the Oxford Technology 3 VCT plc. The Oxford Technology VCT plc has
subscribed for 166,667 New Ordinary Shares and the Oxford Technology 3 VCT plc
has also subscribed for 166,667 New Ordinary Shares under the Open Offer. After
Admission of the New Ordinary Shares the total holding of the Oxford Technology
VCT plc in the Company will amount to 833,330 ordinary shares (representing
5.41 per cent. of the enlarged issued share capital) and the total holding of
the Oxford Technology 3 VCT plc in the Company will amount to 442,592 ordinary
shares (representing 2.87 per cent. of the enlarged issued share capital).

David Evans, Chairman of Scancell Holdings plc, commented:

"We are very pleased that the Open Offer has been so well supported by existing
shareholders.

The net proceeds of the Open Offer, together with the existing funds held by or
available to the Group, will be used to build on the progress achieved since
the Company's admission to PLUS and will be sufficient to allow completion of
the Phase I and Phase IIa Clinical Trial of Scancell's lead melanoma vaccine,
SC1B1."

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For Further Information:

David Evans                     Scancell Holdings Plc    + 44 774 008 4452   
                                                                             
Professor Lindy Durrant         Scancell Holdings Plc    + 44 207 245 1100   
                                                                             
Kirsty Corcoran/John Bick       Hansard Communications   + 44 207 245 1100   
                                                                             
Ross Andrews / Tom Rowley       Zeus Capital             + 44 161 831 1512   

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and is expected to enter clinical trials in Q2 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.